切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2021, Vol. 15 ›› Issue (01) : 4 -10. doi: 10.3877/cma.j.issn.1674-0807.2021.01.002

所属专题: 文献

论著

18F-氟代脱氧葡萄糖正电子发射计算机体层显像在超声乳腺影像报告和数据系统3~5类病变中的诊断价值
何婷婷1, 施彦坤1, 苑克慧1, 胡蓉蓉1, 黄江山1, 陈亮1, 王瑞民2,()   
  1. 1. 572013 三亚,解放军总医院海南医院核医学科
    2. 100853 北京,解放军总医院第一医学中心核医学科
  • 收稿日期:2018-12-17 出版日期:2021-02-01
  • 通信作者: 王瑞民
  • 基金资助:
    国家自然科学基金项目(81450023); 三亚市医疗卫生科技创新项目(2015YW27)

Diagnostic value of 18F-FDG PET/CT imaging in breast imaging reporting and data system ultrasound category 3-5 lesions

Tingting He1, Yankun Shi1, Kehui Yuan1, Rongrong Hu1, Jiangshan Huang1, Liang Chen1, Ruimin Wang2,()   

  1. 1. Department of Nuclear Medicine, Hainan General Hospital of PLA, Sanya 572013, China
    2. Department of Nuclear Medicine, First Medical Center of PLA General Hospital, Beijing 100853, China
  • Received:2018-12-17 Published:2021-02-01
  • Corresponding author: Ruimin Wang
引用本文:

何婷婷, 施彦坤, 苑克慧, 胡蓉蓉, 黄江山, 陈亮, 王瑞民. 18F-氟代脱氧葡萄糖正电子发射计算机体层显像在超声乳腺影像报告和数据系统3~5类病变中的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2021, 15(01): 4-10.

Tingting He, Yankun Shi, Kehui Yuan, Rongrong Hu, Jiangshan Huang, Liang Chen, Ruimin Wang. Diagnostic value of 18F-FDG PET/CT imaging in breast imaging reporting and data system ultrasound category 3-5 lesions[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(01): 4-10.

目的

探讨18F-氟代脱氧葡萄糖正电子发射计算机体层显像(18F-FDG PET/CT)在超声BI-RADS 3~5类病变中的诊断价值。

方法

依据纳入、排除标准,选取2012年1月至2018年10月在解放军总医院第一医学中心就诊的76例乳腺超声诊断为BI-RADS 3~5类病变(77个病变)的患者进行回顾性研究。患者均行乳腺超声BI-RADS分类及18F-FDG PET/CT检查[评价指标为最大标准摄取值(SUVmax)],比较2种方法的诊断效能。2组间SUVmax的比较采用独立样本t检验,多组间SUVmax的比较采用单因素方差分析,组间两两比较采用Tamhane法。以病理诊断作为金标准,绘制ROC曲线并计算曲线下面积(AUC),应用Medcalc软件对2种方法的AUC进行比较。2种方法敏感度、特异度、阳性预测值及正确率等的比较,采用配对χ2检验或χ2检验。

结果

在超声BI-RADS 3~5类病变中,恶性病变SUVmax明显大于良性病变(7.6±4.5比1.8±0.8,t=8.30,P<0.001),并且在超声BI-RADS 4类病变中,恶性病变SUVmax也大于良性病变(6.9±4.5比1.6±0.7,t=-5.552,P<0.001)。超声BI-RADS 3、4、5类病变SUVmax分别为2.2±1.3、5.2±4.2和10.1±5.5,三者比较,差异有统计学意义(F=14.68,P<0.001),并且,随着超声BI-RADS分类程度的增加,SUVmax呈递增趋势。ROC曲线分析显示:超声BI-RADS 3~5类病变中,SUVmax的AUC值为0.931(95%CI: 0.877~0.984),而超声BI-RADS分类的AUC值为0.789(95%CI: 0.684~0.894),两者比较,差异有统计学意义(Z=3.044,P=0.002)。以约登指数最大值确定的SUVmax临界值为3.3,SUVmax诊断的特异度及阳性预测值分别为100%(23/23)和100%(44/44),超声BI-RADS分类诊断的特异度和阳性预测值分别为43.5%(10/23)和79.7%(51/64),两者比较,差异均有统计学意义(P<0.001;χ2=10.161,P=0.001),而SUVmax的敏感度与超声BI-RADS分类相比,差异无统计学意义[81.5%(44/54)比94.4%(51/54),P=0.065]。

结论

在BI-RADS 3~5类病变中,18F-FDG PET/CT诊断效能高于超声BI-RADS分类,在判断乳腺病变良恶性方面有一定的诊断价值;尤其在超声BI-RADS 4类病变中,SUVmax有助于补充判别部分超声亚分类的结果。

Objective

To investigate the diagnostic value of 2-[fluorine 18] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET-CT) imaging in the breast imaging reporting and data system (BI-RADS) ultrasound category 3-5 lesions.

Methods

According to the inclusion and exclusion criteria, this retrospective study involved 76 patients with BI-RADS category 3-5 lesions (77 lesions) in the First Medical Center of PLA General Hospital from January 2012 to October 2018. All patients underwent 18F-FDG PET/CT and ultrasound examination. The diagnostic efficiency of the two methods was compared. The max standard of uptake value (SUVmax) was compared between benign and malignant lesions in BI-RADS category 3-5 lesions by independent sample t test. SUVmax was compared among different subcategory by one-way ANOVA, and the Tamhane method was used for pairwise comparison. With pathological result as golden standard, the ROC curve was drawn and the area under the curve (AUC) was calculated in the Medcalc software. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of two methods were compared by paired χ2 test and χ2 test.

Results

Among BI-RADS category 3-5 lesions, SUVmax of malignant lesions was significantly higher than that of benign lesions (7.6±4.5 vs 1.8±0.8, t=8.30, P<0.001). Among BI-RADS category 4 lesions, SUVmax of malignant lesions was significantly higher than that of benign lesions (6.9±4.5 vs 1.6±0.7, t=-5.552, P<0.001). SUVmax of BI-RADS category 3, 4 and 5 lesions was 2.2±1.3, 5.2+ 4.2 and 10.1+ 5.5, indicating a significant difference and an increasing trend (F=14.68, P<0.001). ROC curve analysis showed that SUVmax AUC was 0.931(95%CI: 0.877-0.984)for BI-RADS category 3-5 lesions and 0.789(95%CI: 0.684-0.894)for BI-RADS ultrasound, indicating a significant difference (Z=3.044, P=0.002). The cut off value of SUVmax determined by the maximum Yoden index is 3.3. The specificity and positive predictive value of SUVmax were 100%(23/23) and 100%(44/44), significantly higher than those of BI-RADS ultrasound [43.5%(10/23) and 79.7%(51/64); P<0.001; χ2=10.161, P=0.001]. The sensitivity of SUVmax showed no significant difference compared with BI-RADS ultrasound [81.5%(44/54) vs 94.4%(51/54), P=0.065].

Conclusions

The diagnostic efficiency of 18F-FDG PET / CT is higher than that of BI-RADS ultrasound in BI-RADS category 3-5 lesions, so 18F-FDG PET / CT is effective for differentiated diagnosis of breast benign and malignant lesions. In BI-RADS ultrasound category 4 lesions, SUVmax was helpful to judge the lesions of ultrasound subcategory.

图1 右侧乳腺癌患者18F-FDG PET/CT检查结果 a图所示18F-FDG PET/CT中CT横断位图像;b图所示18F-FDG PET/CT中PET横断位图像;c图所示18F-FDG PET/CT融合横断位图像
图2 右侧乳腺癌患者病理检查结果(HE ×400)
表1 2种方法对77个乳腺超声BI-RADS 3~5类病变的诊断效能比较
图3 2种检查方法诊断乳腺超声BI-RADS 3~5类病变的受试者工作特征曲线
表2 77个乳腺超声BI-RADS 3~5类病变的18F-FDG PET/CT SUVmax
表3 2种方法对32个乳腺超声BI-RADS 4类病变的诊断效能比较
图4 2种检查方法诊断乳腺超声BI-RADS 4类病变的受试者工作特征曲线
[1]
Mendelson EB, Böhm-Vélez M, Berg WA, et al. ACR BI-RADS ultrasound: ACR BI-RADS atlas, breast imaging reporting and data system[M]. 5th ed. Reston VA: American College of Radiology, 2013.
[2]
Groheux D, Cochet A, Humbert O, et al.18F-FDG PET/CT for staging and restaging of breast cancer[J]. J Nucl Med, 2016,57 Suppl 1:17S-26S.
[3]
Diao W, Tian F, Jia Z. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer[J]. Eur J Radiol, 2018,105:1-7.
[4]
Groheux D, Giacchetti S, Delord M, et al. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer[J]. Eur J Nucl Med Mol Imaging, 2015,42(3):377-385.
[5]
Cochet A, David S, Moodie K, et al. The utility of 18F-FDG PET/CT for suspected recurrent breast cancer: Impact and prognostic stratification[J]. Cancer Imaging, 2014,14(1):13.
[6]
潘中允. 实用核医学[M]. 北京:人民卫生出版社,2014:152-157.
[7]
陈卉,李冬果.医学统计方法及SPSS实现[M].北京:科学出版社,2019:145-161.
[8]
胡瀚中,张松松,曹永政.弹性指数差在鉴别乳腺影像报告数据系统3~5类乳腺肿块良恶性中的应用[J].中国医学影像技术,2017,33(5):662-665.
[9]
Buchberger W, Geiger-Gritsch S, Knapp R, et al. Combined screening with mammography and ultrasound in a population-based screening program[J]. Eur J Radiol, 2018,101:24-29.
[10]
Baba S, Isoda T, Maruoka Y, et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging[J]. J Nucl Med,2014,55(5):736-742.
[11]
Yoon HJ, Kim Y, Kim BS. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ[J]. Eur Radiol, 2015,25(12):3648-3658.
[12]
Shin KM, Kim HJ, Jung SJ, et al. Incidental breast lesions identified by (18)F-FDG PET/CT: Which clinical variables differentiate between benign and malignant breast lesions? [J]. J Breast Cancer, 2015,18(1):73-79.
[13]
Spinelli Varella MA, Teixeira da Cruz J, Rauber A.Role of BI-RADS ultrasound subcategories 4A to 4C in predicting breast cancer[J]. Clin Breast Cancer,2018,18(4):e507-e511.
[14]
陈匆聪,徐雷,祝兰华,等.乳腺超声BI-RADS 4A级病变良恶性的回顾性分析[J].中华乳腺病杂志(电子版),2016,10(5):282-286.
[15]
于鹏,王瑞民,徐白萱,等.超声乳腺影像报告和数据系统与18F-FDG PET/CT在乳腺疾病诊断中的相关性及联合应用价值[J].中国医学影像学杂志,2014,22(10):730-734.
[16]
Dong A, Wang Y, Lu J, et al. Spectrum of the breast lesions with increased 18F-FDG uptake on PET/CT[J]. Clin Nucl Med, 2016,41(7): 543-557.
[1] 章建全, 程杰, 陈红琼, 闫磊. 采用ACR-TIRADS评估甲状腺消融区的调查研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 966-971.
[2] 罗辉, 方晔. 品管圈在提高甲状腺结节细针穿刺检出率中的应用[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 972-977.
[3] 杨忠, 时敬业, 邓学东, 姜纬, 殷林亮, 潘琦, 梁泓, 马建芳, 王珍奇, 张俊, 董姗姗. 产前超声在胎儿22q11.2 微缺失综合征中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 852-858.
[4] 孙佳丽, 金琳, 沈崔琴, 陈晴晴, 林艳萍, 李朝军, 徐栋. 机器人辅助超声引导下经皮穿刺的体外实验研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 884-889.
[5] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[6] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[7] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[8] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[9] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[10] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[11] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[12] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[13] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[14] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[15] 张琛, 秦鸣, 董娟, 陈玉龙. 超声检查对儿童肠扭转缺血性改变的诊断价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 565-568.
阅读次数
全文


摘要